Journal of Hematology & Oncology

official impact factor 2.93

This article is part of the supplement: Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008

Open Access

Molecular target therapy – towards curative regimen: a 20-year experience in the treatment of acute promyelocytic leukemia (APL) in the Shanghai Institute of Hematology

Zhi-Xiang Shen

Journal of Hematology & Oncology 2009, 2(Suppl 1):A1 doi:10.1186/1756-8722-2-S1-A1

Accesses  

  • Last 30 days: 28 accesses
  • Last 365 days: 424 accesses
  • All time: 1458 accesses